Menu Search
Equities

Karadanote Inc

4014:TYO

Karadanote Inc

Actions
Health CareHealth Care Providers
  • Price (JPY)590.00
  • Today's Change2.00 / 0.34%
  • Shares traded36.20k
  • 1 Year change-18.96%
  • Beta2.1160
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Karadanote Inc grew revenues 6.69% from 2.06bn to 2.19bn while net income improved from a loss of 372.46m to a gain of 114.89m.
Gross margin67.58%
Net profit margin5.24%
Operating margin4.30%
Return on assets10.82%
Return on equity31.50%
Return on investment18.53%
More ▼

Cash flow in JPYView more

In 2024, cash reserves at Karadanote Inc fell by 203.17m. Cash Flow from Investing was negative at 3.00m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 107.37m for operations while cash used for financing totalled 92.80m.
Cash flow per share8.35
Price/Cash flow per share71.82
Book value per share56.19
Tangible book value per share55.76
More ▼

Balance sheet in JPYView more

Karadanote Inc has a Debt to Total Capital ratio of 45.97%, a lower figure than the previous year's 79.63%.
Current ratio1.94
Quick ratio1.87
Total debt/total equity0.8507
Total debt/total capital0.4597
More ▼

Growth rates in JPY

Year on year, growth in earnings per share excluding extraordinary items increased 130.59%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)7.67
EPS (TTM) vs
TTM 1 year ago		130.59
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.